(Note: While the authors stated serum in the publication, the blood samples were collected in EDTA tubes. Thus, in the following summary, serum is corrected to plasma.)
Autologous dendritic cells (DC) as a therapeutic vaccine for cancer was designed to harness natural host immunity to improve cancer treatment. However, DC vaccines have only demonstrated limited clinical success. The variables associated with isolation and differentiation of DCs is just one major factor that contributes to differing efficacy. Additionally, the tumor microenvironment of the patient may be immunosuppressive enough to overcome the DC vaccine. The study’s authors collected plasma prior to treating patients with metastatic melanoma with expanded DCs pulsed with autologous tumor cell lysate. This report examined correlation of plasma immune biomarkers in response to DC vaccine therapy.